CORRECTED - Moody's weighs ratings as drug-patent lapses near

(Reuters) - NEW YORK, July 10 - Moody's Investors Service on
Tuesday said a wave of patent expirations on blockbuster drugs
between 2010 and 2012 could lead it to begin lowering its
credit ratings on a number of large U.S. drugmakers several
years before then.




Eli Lilly and Co. , Pfizer Inc. and
Bristol-Myers Squibb Co. are particularly vulnerable to
the downgrades because the top-selling drug of each expires in
that period.


Read more at Reuters.com Government Filings News

Sanofi chairman favors Bristol-Myers deal: paper

(Reuters) - At the same time, Chief Executive Gerard Le Fur has emphasized the need to focus on Sanofi's internal drug research and development program, it reported.

The Times cited unnamed banking sources as saying there was a "significant difference" in tactics between the pair.


Read more at Reuters.com Business News